Although we did not find a significant prognostic value of MSN and CLDN7 in predicting disease outcome in patients with endometrial cancer, our data suggests that MSN and CLDN7 protein immunoexpression might be involved in the development and progression of carcinoma of the endometrium. This evidence concerns the gene CLDN7 and endometrial carcinoma.